Loading stock data…
XOMAO
$25.45+0.01 (+0.04%)
After Hours$25.44-0.01 (-0.04%)· Last close Jun 29
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
XOMA Royalty Corporation in the Healthcare sector is trading at $25.45. The stock is currently 4% below its 52-week high of $26.40, remaining 2.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $310,000↓ | $1.43M↑ | $532,000↓ | $5.38M↑ | $4.32M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$480,000↓ | $2.18M↑ | -$1.33M↓ | $4.60M↓ | $5.93M |
| Net Income | $4.46M↓ | $6.10M↓ | $14.05M↑ | $9.19M↑ | $2.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.95%
Volume
Today's trading volume
7,642
Recent News
XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition
The fair value price target for XOMA Royalty has been reset from US$65.75 to US$39.00, now aligned with the agreed all cash acquisition price. Analysts are centering their narratives on this US$39 level as the key reference point for both valuation and deal related risk, which is shaping how they frame upside and downside from here. As you read on, you will see how this updated target fits into the evolving story around XOMA Royalty and what to watch as the transaction process moves...
Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal
Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech stocks jumped.
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
After announcing healthy earnings, XOMA Royalty Corporation's ( NASDAQ:XOMA ) stock rose over the last week. While the...
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig